Response of @entity1960 to intravenous or oral XXXX ( @entity1140 ).

@entity1 @entity8 @entity101 @entity500 @entity31 @entity4446 @entity205 @entity1960 @entity400 @entity281 @entity1140 @entity230 @entity4854
Intravenous @entity205 has proven to be an alternative to emergency colectomy in steroid-refractory @entity31 , whereas the experience with @entity1140 is limited. In this report we compare intravenous to oral @entity1140 treatment in 38 @entity1 with refractory ulcerative (n = 33) or indeterminate (n = 5) @entity1960 . @entity1140 was started intravenously in the first group (n = 18) at a dose of 0.01 to 0.02 mg/kg up to 14 days, followed by 0.1 to 0.2 mg/kg orally, or was started orally at this dose in a second group (n = 20). Additional @entity500 / @entity4446 was given and @entity230 were tapered in responding @entity1 , followed by a dose reduction of @entity1140 . Clinical disease activity and laboratory parameters were assessed to evaluate efficacy and safety. Primary objectives were the induction of remission (Truelove index of mild) and colectomy-free survival. Treatment lasted for a mean of 7.6 months, and the mean observation period was 16.2 months. Eighteen of 38 @entity1 improved within 14 days, and a complete remission was achieved in 13 @entity1 after 1 month. A colectomy within 1 month was performed in 3 of 38 @entity1 . The overall colectomy rate was 34%. One-half of the @entity1 with a minimum follow-up of 2 years required a colectomy. Intravenous and per oral administration were equally safe and effective. The most frequent adverse events included @entity400 , @entity4854 , @entity101 , and @entity281 , but none were severe. @entity8 was rare and subsided upon drug withdrawal. In conclusion. @entity1140 is effective in the treatment of @entity1960 with per oral dosing being equivalent to intravenous administration.
